Literature DB >> 29191843

Expression of programmed death-1 on lymphocytes in myeloma patients is lowered during lenalidomide maintenance.

Sophia Danhof1, Martin Schreder2, Stefan Knop2, Leo Rasche2, Susanne Strifler2, Claudia Löffler2, Tea Gogishvili2, Hermann Einsele2, Michael Hudecek2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29191843      PMCID： PMC5830376          DOI： 10.3324/haematol.2017.178947

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  16 in total

1.  Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.

Authors:  Güllü Görgün; Mehmet K Samur; Kristen B Cowens; Steven Paula; Giada Bianchi; Julie E Anderson; Randie E White; Ahaana Singh; Hiroto Ohguchi; Rikio Suzuki; Shohei Kikuchi; Takeshi Harada; Teru Hideshima; Yu-Tzu Tai; Jacob P Laubach; Noopur Raje; Florence Magrangeas; Stephane Minvielle; Herve Avet-Loiseau; Nikhil C Munshi; David M Dorfman; Paul G Richardson; Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2015-05-15       Impact factor: 12.531

2.  PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine.

Authors:  Jacalyn Rosenblatt; Brett Glotzbecker; Heidi Mills; Baldev Vasir; Dimitrios Tzachanis; James D Levine; Robin M Joyce; Kerry Wellenstein; Whitney Keefe; Michael Schickler; Rinat Rotem-Yehudar; Donald Kufe; David Avigan
Journal:  J Immunother       Date:  2011-06       Impact factor: 4.456

3.  Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.

Authors:  F E Davies; N Raje; T Hideshima; S Lentzsch; G Young; Y T Tai; B Lin; K Podar; D Gupta; D Chauhan; S P Treon; P G Richardson; R L Schlossman; G J Morgan; G W Muller; D I Stirling; K C Anderson
Journal:  Blood       Date:  2001-07-01       Impact factor: 22.113

4.  T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy.

Authors:  David J Chung; Katherine B Pronschinske; Justin A Shyer; Sneh Sharma; Samantha Leung; Shane A Curran; Alexander M Lesokhin; Sean M Devlin; Sergio A Giralt; James W Young
Journal:  Cancer Immunol Res       Date:  2015-10-13       Impact factor: 11.151

5.  Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients.

Authors:  A Busch; D Zeh; V Janzen; L-O Mügge; D Wolf; L Fingerhut; C Hahn-Ast; O Maurer; P Brossart; M von Lilienfeld-Toal
Journal:  Clin Exp Immunol       Date:  2014-08       Impact factor: 4.330

6.  Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma.

Authors:  Ashraf Badros; Elizabeth Hyjek; Ning Ma; Alexander Lesokhin; Ahmet Dogan; Aaron P Rapoport; Mehmet Kocoglu; Emily Lederer; Sunita Philip; Todd Milliron; Cameron Dell; Olga Goloubeva; Zeba Singh
Journal:  Blood       Date:  2017-05-01       Impact factor: 22.113

7.  Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes.

Authors:  Y Agata; A Kawasaki; H Nishimura; Y Ishida; T Tsubata; H Yagita; T Honjo
Journal:  Int Immunol       Date:  1996-05       Impact factor: 4.823

8.  Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro.

Authors:  Patrick A J Haslett; Willem A Hanekom; George Muller; Gilla Kaplan
Journal:  J Infect Dis       Date:  2003-03-06       Impact factor: 5.226

9.  Lenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis.

Authors:  Emmanuel Clave; Corinne Douay; Tereza Coman; Marc Busson; Caroline Bompoint; Helene Moins-Teisserenc; Salomé Glauzy; Maryvonnick Carmagnat; Norbert Claude Gorin; Antoine Toubert; Laurent Garderet
Journal:  Leuk Lymphoma       Date:  2013-12-31

10.  Lenalidomide after stem-cell transplantation for multiple myeloma.

Authors:  Philip L McCarthy; Kouros Owzar; Craig C Hofmeister; David D Hurd; Hani Hassoun; Paul G Richardson; Sergio Giralt; Edward A Stadtmauer; Daniel J Weisdorf; Ravi Vij; Jan S Moreb; Natalie Scott Callander; Koen Van Besien; Teresa Gentile; Luis Isola; Richard T Maziarz; Don A Gabriel; Asad Bashey; Heather Landau; Thomas Martin; Muzaffar H Qazilbash; Denise Levitan; Brian McClune; Robert Schlossman; Vera Hars; John Postiglione; Chen Jiang; Elizabeth Bennett; Susan Barry; Linda Bressler; Michael Kelly; Michele Seiler; Cara Rosenbaum; Parameswaran Hari; Marcelo C Pasquini; Mary M Horowitz; Thomas C Shea; Steven M Devine; Kenneth C Anderson; Charles Linker
Journal:  N Engl J Med       Date:  2012-05-10       Impact factor: 91.245
View more
  8 in total

Review 1.  Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs.

Authors:  Criselle D'Souza; H Miles Prince; Paul J Neeson
Journal:  Front Immunol       Date:  2021-03-05       Impact factor: 7.561

2.  Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy.

Authors:  Sophia Danhof; Susanne Strifler; Dorothea Hose; Martin Kortüm; Max Bittrich; Jochen Hefner; Hermann Einsele; Stefan Knop; Martin Schreder
Journal:  J Cancer Res Clin Oncol       Date:  2018-12-05       Impact factor: 4.322

3.  Immunomodulatory Drugs in the Context of Autologous Hematopoietic Stem Cell Transplantation Associate With Reduced Pro-tumor T Cell Subsets in Multiple Myeloma.

Authors:  Giulia Di Lullo; Magda Marcatti; Silvia Heltai; Cristina Tresoldi; Anna Maria Paganoni; Claudio Bordignon; Fabio Ciceri; Maria Pia Protti
Journal:  Front Immunol       Date:  2019-01-21       Impact factor: 7.561

4.  Quantitative and functional characteristics of circulating and bone marrow PD-1- and TIM-3-positive T cells in treated multiple myeloma patients.

Authors:  Egor V Batorov; Tatiana A Aristova; Vera V Sergeevicheva; Svetlana A Sizikova; Galina Y Ushakova; Natalia V Pronkina; Irina V Shishkova; Ekaterina Y Shevela; Alexander A Ostanin; Elena R Chernykh
Journal:  Sci Rep       Date:  2020-11-30       Impact factor: 4.379

Review 5.  Checkpoint Inhibitors and Engineered Cells: New Weapons for Natural Killer Cell Arsenal Against Hematological Malignancies.

Authors:  Massimo Giuliani; Alessandro Poggi
Journal:  Cells       Date:  2020-06-29       Impact factor: 6.600

Review 6.  A Journey Through Myeloma Evolution: From the Normal Plasma Cell to Disease Complexity.

Authors:  Matteo C Da Vià; Bachisio Ziccheddu; Akihiro Maeda; Filippo Bagnoli; Giulia Perrone; Niccolò Bolli
Journal:  Hemasphere       Date:  2020-11-24

7.  Single-cell transcriptome profiling reveals the key role of ZNF683 in natural killer cell exhaustion in multiple myeloma.

Authors:  Xin Li; Mengping Chen; Yike Wan; Lu Zhong; Xiaofeng Han; Xiaotong Chen; Fei Xiao; Jia Liu; Yiwei Zhang; Di Zhu; Jing Xiang; Junling Liu; Honghui Huang; Jian Hou
Journal:  Clin Transl Med       Date:  2022-10

8.  Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma.

Authors:  Manh-Cuong Vo; Sung-Hoon Jung; Tan-Huy Chu; Hyun-Ju Lee; Thangaraj Jaya Lakshmi; Hye-Seong Park; Hyeoung-Joon Kim; Joon Haeng Rhee; Je-Jung Lee
Journal:  Front Immunol       Date:  2018-06-18       Impact factor: 7.561
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.